Jean-Marie Ruxer

This inventor holds 24 USPTO granted patents and 1 published patent application, plus 1 CIPO patent and 7 EPO patents, primarily in Pharmaceutical Compositions. Top assignees: Genentech, Inc., Sanofi-Aventis, Aventis Pharma S.a.. Active years: 1999-2012.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Jean-Marie Ruxer. Retrieved from https://idiyas.com/inventor/jean-marie-ruxer

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 24 (Patent Applications = 1)

% Patents Active = 62.5

CIPO Patents = 1

EPO Patents = 7 (Patent Applications = 3)

Average Co-Inventor Count = 5.8

ph-index = 5

Forward Citations = 98(Granted Patents)

Location History:

Issy Ies Moulineaux, FR (2002)
Issey les Moulineaux, FR (2005)
Issy les Moulineaux, FR (1999 - 2010)
Paris, FR (2010 - 2012)

Company Filing History:

Hoechst Aktiengesellschaft

Aventis Pharma Deutschland, Gmbh

patents

7. 1 out of 1

Aventis Pharma S.a. Deutschland Gmbh Genentech, Inc.

Sanofi-A Ventis Deutschland Gmbh

patents

10. 8 out of 834,570

Other

patents

where one patent can have more than one assignee

Years Active: 1999-2012

Loading Chart...

Areas of Expertise:

HSP90 Inhibitors

Pharmaceutical Compositions

Vitronectin Receptor Antagonists

Fluorene Derivatives

Heterocycles

Cell Adhesion Inhibitors

Pyrroloindole Derivatives

Naphthyridine Derivatives

Acylguanidine Derivatives

Thienylalanine Derivatives

Substituted Purine Derivatives

Guanidino Derivatives

24 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 8309721 - HSP90 inhibitory carbazole derivatives, compositions containing same and use thereof (2012-11-13),

2. 8178687 - Derivatives of pyrroloindole which are inhibitors of Hsp90, compositions containing same, and use thereof (2012-05-15),

3. 8163750 - Fluorene derivatives, compositions containing the same and use thereof as inhibitors of the protein chaperone HSP 90 (2012-04-24),

4. 8044074 - Substituted heterocycles, their use as medicament, and pharmaceutical preparations comprising them (2011-10-25),

5. 7825264 - Substituted heterocycles, their use as medicament, and pharmaceutical preparations comprising them (2010-11-02),

6. 7763621 - Vitronectin receptor antagonist derivatives, method for preparing same, use thereof as medicines and pharmaceutical compositions containing same (2010-07-27),

7. 7674795 - Fluorene derivatives, composition containing said derivatives and the use thereof (2010-03-09),

8. 7582640 - Vitronectin receptor antagonist derivatives, method for preparing same, use thereof as medicines and pharmaceutical compositions containing same (2009-09-01),

9. 7550453 - 2-alkoxy-3,4,5-trihydroxy-alkylamides, preparation thereof, compositions containing them and use thereof (2009-06-23),

10. 7259159 - Guanidino derivatives as inhibitors of cell adhesion (2007-08-21),

11. 6867213 - (2S)-2-(adamantan-1-ylmethoxycarbonylamino)-3-(4-(2-(1,4,5,6-tetrhydropyrimidin-2-ylcarbamoyl)ethyl)benzoylamino)propionic acid isopropyl ester, its preparation and its use (2005-03-15),

12. 6867208 - Vitronectin receptor antagonists, their preparation and their use (2005-03-15),

13. 6838453 - Antagonist derivatives of the vitronectin receptor (2005-01-04),

14. 6762190 - Thienylalanine derivatives as inhibitors of cell adhesion (2004-07-13),

15. 6747016 - Substituted purine derivatives as inhibitors of cell adhesion (2004-06-08),

Title: Jean-Marie Ruxer: Innovator in Pharmaceutical Chemistry

Introduction: Jean-Marie Ruxer, based in Issy les Moulineaux, France, is a prolific inventor with an impressive portfolio of 24 patents. His work primarily focuses on innovative compounds with therapeutic applications, particularly in the field of cancer treatment.

Latest Patents: Among Ruxer's latest patents are notable inventions that involve HSP90 inhibitory carbazole derivatives. These novel substances are defined by a complex formula including various substituents that confer unique drug properties. Another significant invention includes derivatives of pyrroloindole, which also serve as inhibitors of HSP90. These compounds demonstrate potential as effective medications, highlighting Ruxer's dedication to advancing pharmaceutical science through innovative chemistry.

Career Highlights: Throughout his career, Jean-Marie Ruxer has made substantial contributions to the field of drug development. He has worked with renowned companies such as Genentech, Inc., where his expertise has helped influence groundbreaking advancements in pharmaceutical innovation.

Collaborations: Ruxer has collaborated with esteemed colleagues, including Anuschirwan Peyman and Jean-Michel Lefrancois. These partnerships have fostered a rich environment for knowledge exchange and creativity, enabling the development of novel therapeutic agents.

Conclusion: Jean-Marie Ruxer stands out as an influential inventor in the realms of pharmaceutical chemistry and drug discovery. His numerous patents and collaborative efforts with industry leaders underline his commitment to driving innovation and improving healthcare outcomes through his groundbreaking inventions.

Profile summary based on public USPTO records.